Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells

Journal of Dermatology

Volumn 33, Issue 7, 2006, Pages 462-472

  Nakai, Noriaki ^a   Asai, Jun ^a   Ueda, Eiichiro ^a   Takenaka, Hideya ^a   Katoh, Norito ^a   Kishimoto, Saburo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Dendritic cell; Melanoma; Melanoma peptides; Tumor lysate; Vaccination

Indexed keywords

DENDRITIC CELL VACCINE; HLA A2 ANTIGEN; HLA A24 ANTIGEN; MELAN A; MELANOMA ANTIGEN 1[135-143]; MELANOMA ANTIGEN 1[27-35]; MELANOMA ANTIGEN 2[156-163]; MELANOMA ANTIGEN 3[195-203]; MELANOMA ANTIGEN 3[271-279]; MELANOMA PEPTIDE; MONOPHENOL MONOOXYGENASE; STEROID; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL LYSATE; CELL MATURATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DERMATITIS; DISEASE COURSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; EOSINOPHILIA; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INFLAMMATION; INGUINAL LYMPH NODE; MALE; MELANOMA; METASTASIS; MONOCYTE; SKIN INDURATION; TREATMENT OUTCOME; TUMOR ESCAPE; TUMOR LYSATE;

ADULT; AGED; ANTIGENS, NEOPLASM; ASIAN CONTINENTAL ANCESTRY GROUP; DENDRITIC CELLS; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ADOPTIVE; MALE; MELANOMA; MIDDLE AGED; PEPTIDES; SKIN NEOPLASMS; TISSUE EXTRACTS; TREATMENT OUTCOME;

EID: 33745569040     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2006.00110.x     Document Type: Article

References (25)

1. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
2. 280-288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 2001; 7: 3012-3024.
3. Bettinotti MP, Panelli MC, Ruppe E et al. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12: 170-178. Int J Cancer 2003; 105: 210-216.
4. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332.
5. Nagayama H, Sato K, Morishita M et al. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Research 2003; 13: 521-530.
6. Akiyama Y, Tanosaki R, Inoue N et al. Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. Journal of Translational Medicine 2005; 3: 4-13.
7. + progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451-6458.
8. Palucka AK, Dhodapkar MV, Paczesny S et al. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother 2003; 26: 432-439.
9. Slingluff CL, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21: 4016-4026.
10. Schuler-Thurner B, Schultz ES, Berger TG et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195: 1279-1288.
11. Tüting T, Wilson CC, Martin DM et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α. J Immunol 1998; 160: 1139-1147.
12. Goxe B, Latour N, Bartholeyns J, Romet-Lemonne JL, Chokri M. Monocyte-derived dendritic cells: development of a cellular processor for clinical applications. Res Immunol 1998; 149: 643-646.
13. Jonuleit H, Kühn U, Müller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135-3142.
14. Thurner B, Röder C, Dieckmann D et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999; 223: 1-15.
15. Zhang X, Gordon JR, Xiang J. Advances in dendritic cell-based vaccine of cancer. Cancer Biother Radiopharm 2002; 17: 601-619.
16. Onaitis M, Kalady MF, Pruitt S, Tyler DS. Dendritic cell gene therapy. Surg Oncol Clin N Am 2002; 11: 645-660.
17. Spisek R, Bretaudeau L, Barbieux I, Meflah K, Gregoire M. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother 2001; 50: 417-427.
18. Marincola FM, Shamamian P, Alexander RB et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994; 153: 1225-1237.
19. Kageshita T, Wang Z, Calorini L et al. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 1993; 53: 3349-3354.
20. Geertsen RC, Hofbauer GFL, Yue FY, Manolio S, Burg G, Dummer R. Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than primary melanoma lesions. J Invest Dermatol 1998; 111: 497-502.
21. Martin E, O'Sullivan B, Low P, Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 2003; 18: 155-167.
22. Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 2004; 65: 794-802.
23. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9: 606-612.
24. Thurner B, Haendle I, Röder C et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 11: 1669-1678.
25. Berard F, Blanco P, Davoust J et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 11: 1535-1543.